Rovalpituzumab tesirine (SC16LD6.5), an antibody‐drug conjugate targeting DLL3, has shown promising results in phase I studies against SCLC and large‐cell NE tumours, demonstrating encouraging single‐agent anti‐tumour activity and a manageable safety profile. Here, DLL3 is linked to neoplasm.